Arca
Skip to content
Tools
Tools

Enalapril Maleate Tablets

Recall D-0979-2018, part of FDA recall event 80463. See Major Pharmaceuticals's company page.

MAJOR PHARMACEUTICALS started this Class III drug recall on Jun 26, 2018 (voluntary: firm initiated); FDA lists it as terminated, terminated Apr 10, 2019.

  • Classification: Class III
  • Started: Jun 26, 2018
  • Status: Terminated
  • Products in this event: 2

Why It Was Recalled

Class III

Failed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification results for the Enalapril DiKetopiperazine degradation product.

Record

Product
Enalapril Maleate Tablets, USP, 2.5 mg, 100 Tablets (10 x 10) Unit Dose per carton, Rx only, Manufactured by: Wockhardt Limited, H-14/2, M.I.D.C. Area, Waluj, Aurangabad, Maharashtra, India; Distributed by: Wockhardt USA LLC., 20 Waterview Blvd., Parsippany, NJ 07054; Distributed by: MAJOR Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152; NDC 0904-5609-61.
Quantity
3,397 cartons
Lots and codes
Lot #: T-01083, Exp 08/18; DR10447A, Exp 09/18; DS10201A, Exp 07/19; DS10201B, DS10201C, Exp 08/19; DS10319A, Exp 10/19.
Distribution
Nationwide in the USA and Puerto Rico.
Recalling firm
MAJOR PHARMACEUTICALS, Livonia, MI, United States
How the firm notified
N/A
FDA classified
Jul 24, 2018

Other Products in This Recall

Recall event 80463

MAJOR PHARMACEUTICALS's Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.